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BACKGROUND:  Extraskeletal  myxoid  chondrosarcoma  (EMC)  accounts  for  the  3%  of  all  soft  tissue  sar-
comas  and  it’s categorized  as  a  tumour  of  uncertain  differentiation.  This  entity  has  shown  to  have  the
recurrent  balanced  chromosomal  translocation  t(9;22)  (q22;q12.2),  which  leads  to the  oncogenic  fusion
gene  EWSR1-NR4A3.  This  sarcoma  usually  presents  as a slow  growing,  palpable  mass  in  the  extremities.
EMC  arising  from  the  lung  is  extremely  infrequent.  We  report one  case  of pulmonary  extraskeletal  mixoid
chondrosarcoma  and a review  of the  world  literature.
CASE REPORT:  A 69-year-old  male  patient  presented  with  intermittent  hemoptysis  for  the  last 6  months.  A
PET/CT scan  showed  a hypermetabolic  solid  mass  with  lobulated  borders  of  approximately  29  × 26  mm  in
the inferior  right  lobe.  We  performed  a right  thoracotomy  with  inferior  lobectomy  and  lymphadenectomy
of  levels  VII, VIII,  X,  and  XI  levels.  The  neoplasm  was  constituted  by cords  of  small  cells  with  small
round  nucleus  and  scarce  cytoplasm  immerse  in  an abundant  myxoid  matrix.  The immunophenotype
was  positive  for MUM-1,  CDK4,  MDM2,  and  showed  focal  expression  for S-100 protein  and  CD56.  The
ﬁnal  pathology  report  revealed  a  pulmonary  extraskeletal  mixoid  chondrosarcoma.  No  further  surgical
interventions  or adjuvant  therapies  were  needed.
CONCLUSION:  EMC  is  an  intermediate-grade  neoplasm,  characterized  by a long  clinical  course  with  high
potential  for  local  recurrence  and  distant  metastasis.  Treatment  for EMC  is  surgical  and  non-surgical  treat-
ment is reserved  for  recurrence  or metastatic  disease.  Pulmonary  extraskeletal  myxoid  chondrosarcoma
is a  rare neoplasm  with  only  isolated  case  reports  found  in  the  literature.
© 2016  Published  by Elsevier  Ltd on  behalf  of  IJS Publishing  Group  Ltd.  This  is  an  open  access  article
he CCunder  t
. Introduction
Extraskeletal myxoid chondrosarcoma (EMC) is a rare tumour
f uncertain differentiation ﬁrst described by Stout and Verner in
953 [1,2]. The clinicopathological features of this sarcoma were
ot described until 1972 by Enzinger and Shiraki [3]. EMC  has
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ialidad de la Barranca s/n, Col. Valle de las Palmas Huixquilucan, Estado de México,
.P. 52763, Mexico.
E-mail address: rodrigo.arrangoiz@gmail.com (R. Arrangoiz).
ttp://dx.doi.org/10.1016/j.ijscr.2016.08.025
210-2612/© 2016 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This i
rg/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
shown to have the recurrent balanced chromosomal transloca-
tion t(9;22) (q22;q12.2), which leads to the oncogenic fusion gene
EWSR1-NR4A3 [4]. This chimeric gene activates the transcription
of target genes involved in cell proliferation and has been detected
in approximately 65% of the cases [5]. Histologically, EMC  has
a marked phenotypic plasticity that overlaps with mesenchymal
malignancies, vague resemblance to human cartilage and an uncer-
tain histiogenesis [6]. Immunohistochemical studies in most EMC
are positive for vimentin and focally positive for S100 protein [7].
This sarcoma predominantly affects men  beyond their ﬁfth decade
and normally does not behave in an aggressive way, nevertheless
it has a high rate of local recurrence and distant metastases [5].
s an open access article under the CC BY-NC-ND license (http://creativecommons.
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Fig. 2. Right thoracotomy with inferior pulmonary lobectomy and lymphadenec-
tomy of the VII, VIII, X, and XI levels.ig. 1. PET/CT scan showing a hypermetabolic solid mass located in the lateral
egment of the inferior right pulmonary lobe.
he deep thigh is the most common location of EMC, although
t can be found in the hands, retroperitoneum, head or neck [7].
n EMC  arising from the lung is extremely infrequent and iso-
ated to case reports in the literature [7]. We  present a case of
ulmonary extraskeletal myxoid chondrosarcoma in a 69-year-old
ale patient that presented with intermittent hemoptysis. This
rticle includes the information available in the world literature
ut do to it’s rarity most of this information comes from isolated
ase reports. This case report follows the CARE criteria [8].
. Case report
We  present a 69-year-old male patient with a past medical
istory of hypertension. During the last six months, he experi-
nced intermittent hemoptysis without any other symptom. An
tolaryngologist explored the patient and initiated treatment for
astroesophageal reﬂux disease. In the last month, the patient pre-
ented hemoptysis daily so he decided to get a CT scan of the chest.
he chest CT showed a solid, multilobulated mass of approximately
5 mm on its greater axis located in the right lung (inferior lobe).
here was no other pertinent history. Physical examination was
ormal. A PET/CT scan showed a hypermetabolic solid mass with
obulated borders of approximately 29 × 26 mm located in the lat-
ral segment of the inferior right lobe (Fig. 1).
A right thoracotomy with inferior lobectomy and lymphadenec-
omy of levels VII, VIII, X, and XI levels was performed (Fig. 2).
ymphadenectomy was performed because our preoperative pre-
umptive diagnosis was an adenocarcinoma of the lung. The
ight inferior lobe was extracted with a tumour of approximately
 × 3 cm (Fig. 3). The neoplasm was constituted by cords of small
ells with small round nucleus and scarce cytoplasm immerse in
n abundant myxoid matrix (Figs. 4 and 5). The immunopheno-
ype was positive for MUM-1, CDK4, MDM2,  and showed focal
xpression for S-100 protein and CD56. The surgical margins were
egative for malignancy. The ﬁnal pathology report revealed a pul-
onary extraskeletal mixoid chondrosarcoma.
After discussing the case in our multidisciplinary tumour board,
o further surgical intervention or adjuvant therapy was recom-
ended. The patient will have a close follow up. There is noFig. 3. Right inferior pulmonary lobe with a mass of approximately 3 × 3 cm.
evidence of persistent o recurrent disease at six months post-
surgery.
3. Discussion
Extraskeletal myxoid chondrosarcoma (EMC) is a malignant
neoplasm characterized by the multinodular growth of primitive
chondroid cells in an abundant myxoid matrix [9]. EMC  is cat-
egorized as a tumour of uncertain differentiation by the 2002
WHO  classiﬁcation and accounts for approximately three per-
cent of all soft tissue sarcomas [2,4]. EMC  is characterized by
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he presence of various chromosomal translocations that result
n abnormal gene products that affect cellular proliferation and
ifferentiation and ultimately lead to tumorigenesis [4]. The typi-
al translocation found in EMC  is t(9;22)(q22;q11), which results
n the juxtaposition of the gene EWSR1 on chromosome 22
nd the gene NR4A3 on chromosome 9 [6]. The fusion gene
WSR1-NR4A3 has not been detected in any other type of can-
er and seems to constitute a pathognomonic EMC  marker [1].
he translocation t(9;22)(q22;q11) is found in approximately 75%
f EMC’s cases [10]. Alternative translocations found in EMC  are
(9;17)(q22;q11) coding for NR4A3-TAF15 and t(9;15)(q22;q21)
oding for NR4A3-TCF12/HTF4 [6]. Immunophenotypically, EMC
able 1
haracteristics of patients with EMC  diagnosis in ten case series.
Case Series Author Publication Year Number of Cases 
Oliveira et al. [3] 2000 23 
Kawaguchi et al. [9] 2003 42 
Tateishi et al. [17] 2006 19 
Ehara  et al. [2] 2007 4 
Xiu-feng et al. [5] 2008 9 
Drilon et al. [6] 2008 86 
Ogura et al. [5] 2012 23 
Flucke et al. [11] 2012 5 
Stacchiotti et al. [14] 2013 11 
Kapoor et al. [13] 2014 13 PEN  ACCESS
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shows strong vimentin expression, focal S-100 protein expres-
sion, and frequently class III -tubulin and microtubule-associated
protein-2 expression, which are known to be restricted to neural
cells [5].
The differential diagnosis for EMC  include myoepithelial car-
cinoma of soft tissue (MEC), myxoid type of malignant ﬁbrous
histiocytoma, myxoid liposarcoma, mixed tumour of soft tissue,
nodular fasciitis, ganglion cyst, chordoma, myxoid peripheral nerve
sheath tumour, and when arising from the lungs primary pul-
monary myxoid sarcoma (PPMS) [1,11,12]. The histological features
of EMC  partially overlap with PPMS and they occasionally share
focal EMA  and S-100 expresion [11]. PPMS is characterized by
the presence of the chromosomal translocation t(2;22)(q33;q12),
which encodes the oncogenic fusion gene EWSR1-CREB1, while
EMC  is known to express the chimeric gene EWSR1-NR4A3 [11].
MEC  and EMC  arise predominantly in the proximal lower extrem-
ity and itı´s difﬁcult to morphologically distinguish them since they
both exhibit features typically seen in myoepithelial tumors [12].
MECı´s peak incidence is the fourth decade of life, while EMC  fre-
quently arises in the sixth decade [12]. MEC  are normally located
more superﬁcially than EMC  and demonstrate a more aggressive
behaviour [12].
The average age of occurrence of EMC  is around 50 years and
has a male: female ratio of 2: 1 [5,6,13]. In Table 1, we state the
gender and age preferences of EMC  from ten case series published
between 2000 and 2014. EMC  usually presents as a slow grow-
ing palpable mass that causes local pain or tenderness [5]. EMC  is
located in the lower extremities in approximately 62% of the cases,
in the upper extremities in 17% of the cases, and in the abdomen,
retroperitoneum, pelvis, or other locations in 21% of the cases [14].
Table 2 presents the location, size, and metastases at time of diagno-
sis of EMC  in ten case series. The majority of EMC  has a prolonged
clinical course with a 10-year survival rate ranging between 65%
and 85%, and a 15-year survival rate of 58%. A 40% risk of distant
metastases at 10 years has been documented [15,16]. On Table 3
we present the clinical follow up of ten EMCı´s case series. Despite
showing an indolent long term course, EMC  has a high potential for
local recurrence and distant metastasis and should be considered
as an intermediate-grade rather than a low-grade neoplasm [4,6].
The diagnosis of EMC  can be conﬁrmed by demonstrating the
presence of the pathognomonic translocation t(9;22)(q22;q11),
which results in the fusion gene EWSR1-NR4A3 [1,10]. We
reviewed the data from different case series regarding the presence
of EWSR1-NR4A3 gene rearrangement and the immunohistochem-
ical ﬁndings of EMC  and presented it on Table 4. Contrast enhanced
CT show primary EMC  as isodense to slightly hypodense to muscle
with no internal calciﬁcations [14]. On MRI, EMC  is characterized by
multi-nodular soft-tissue masses with hyper-signal intensity on T2
and heterogeneous enhancement after administration of contrast
material [14,17]. EMC  expressing the fusion gene EWSR1-NR4A3
show peripheral enhancement on MR  more frequently than those
with other cytogenetic variants [17]. MRI  is preferred over CT for
Male Female Mean Age Age Range
11 12 50 22–78
20 22 52.1 21–82
12 7 53 16–76
3 1 55.5 44–74
7 2 52.8 31–69
57 29 49.5 15–82
10 13 58 35–79
3 2 57 37–82
9 2 52 38–69
10 3 54 29–73
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Table  2
Size, location, and presence of metastatic disease at time of diagnosis of EMC in ten case series.
Case Series Author Number Size (cm) Location Metastasis
of Cases Mean Range Lower Upper Trunk Lungs Other at Time of Diagnosis
Extremities Extremities
Oliveira et al. [3] 23 9.5 1.5–18.5 19 2 2 0 0 3
Kawaguchi et al. [9] 42 7 1.5–20 28 7 7 0 0 7
Tateishi  et al. [17] 19 8.9 2–20 15 3 1 0 0 1
Ehara  et al. [2] 4 NA NA 3 1 0 0 0 0
Xiu-feng et al. [5] 9 7 4–11 7 1 1 0 0 0
Drilon  et al. [6] 86 6.8 1–30 53 15 11 0 7 10
Ogura  et al. [4] 23 7.8 3–18 14 2 7 0 0 3
Flucke  et al. [11] 5 8.5 1–15 3 1 1 0 0 1
Stacchiotti et al. [14] 11 NA NA 9 1 1 0 0 4
Kapoor  et al. [13] 13 9.3 3.3–18 9 0 4 0 0 5
NA indicates non available.
Table 3
Clinical follow up of EMC  in ten case series.
Case Series Author Number of Cases Clinical Follow Up
Number of Patients
with Clinical
Follow Up
Mean Follow up
Period (Months)
Local Recurrences Metastatic Disease Death
Patients Lungs Bone Other
Oliveira et al. [3] 23 23 111.6 3 8 6 2 0 5
Kawaguchi et al. [9] 42 42 88.8 17 6 4 0 2 3
Tateishi et al. [17] 19 19 61 3 3 3 1 0 2
Ehara et al. [2] 4 4 97.5 2 3 3 3 0 3
Xiu-feng et al. [5] 9 7 93 4 2 2 0 0 2
Drilon et al. [6] 86 86 43.2 27 19 NA NA NA 14
Ogura et al. [4] 23 23 109 9 8 6 3 6 5
Flucke et al. [11] 5 4 61 1 1 0 0 1 0
Stacchiotti et al. [14] 11 10 30 1 7 6 1 5 2
Kapoor et al. [13] 13 12 40.5 3 12 12 3 6 3
NA indicates non available.
Table 4
Presence of ETV6-NTK3 gene rearrangement and immunohistochemical ﬁndings of EMC  in ﬁve case series.
Case Series Author Number EWSR1-NR4A3 Immunohistochemical Findings
of Cases Gene Rearrangement Vimentin Synaptophysin EMA  S-100 Desmin NSE PPAR 
Oliveira et al. [3] 23 NA 16 13 5 3 2 NA NA
Tateishi et al. [17] 19 9 NA NA NA NA NA NA NA
Xiu-feng et al. [5] 9 NA 9 2 0 6 0 7 NA
Flucke et al. [11] 5 4 NA NA 2 2 NA NA NA
Stacchiotti et al. [14] 11 11 NA 1 7 3 NA NA 9
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etection of primary disease or local recurrence because of its abil-
ty to differentiate the neoplasmı´s tissue from unaffected muscle
14].
Surgical intervention is the only satisfactory chance of cure for
MC  [6]. The use of radiotherapy for this malignancy has not been
ell deﬁned but it can be considered in an adjuvant setting or
or palliation of metastatic disease [4]. The use of chemothera-
eutic agents in the treatment of EMC  is controversial and none
as demonstrated a durable efﬁcacy [6]. Stacchiotti et al. reported
hat anthracycline-based chemotherapy is active in a distinct pro-
ortion against EMC  and can be used in case of advanced and
rogressive disease [15]. The use of tirosin-kinase inhibitors like
unitinib may  also have a role in the treatment of EMC, neverthe-
ess there is not enough evidence at the time [16]. Table 5 presents
he treatments used for EMC  in seven case series.Pulmonary extraskeletal myxoid chondrosarcomas are
xtremely rare with only isolated case reports found in the
iterature [7]. The lung is the most frequent site of EMCı´s metas-tases [18]. EMC  of the lung may  present as an asymptomatic mass
or with hemoptysis, dyspnea or anemia [18–20]. The treatment
and prognosis regarding EMC  of the lung can only be extrap-
olated from other cartilaginous tumour types because of the
lack of good evidence in literature [7]. We  found four cases of
pulmonary extraskeletal myxoid chondrosarcoma in the literature
and presented them in Table 6.
3. Conclusion
EMC  is a tumour of uncertain differentiation ﬁrst described in
1953 by Stout and Verner. This malignant neoplasm is charac-
terized by the multinodular growth of primitive chondroid cells
in an abundant myxoid matrix. This tumor is characterized by
the translocation t(9;22)(q22;q11) which encodes for the fusion
gene EWSR1-NR4A3. This translocation is pathognomonic for EMC
and is present in approximately 75% of the cases. EMC  has a
predilection for male patients and its peak incidence is in the sixth
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Table  5
Treatment of EMC  in seven case series.
Case Series
Author
Number of
Cases
Treatment
Marginal
Excision
Wide Local
Excision
Amputa- tion Radio-
therapy
Preoperative
Radiotherapy
Postoperative
Radiotherapy
Chemo-
therapy
Preoperative
Chemotherapy
Postoperative
Chemotherapy
Oliveira et al. [3] 23 2 17 4 10 2 9 1 1 0
Kawaguchi et al. [9] 42 3 30 5 6 1 5 7 0 6
Tateishi et al. [17] 19 11 8 0 1 0 1 1 0 1
Drilon et al. [6] 86 0 73 0 22 NA NA 21 21 21
Ogura et al. [4] 23 11 8 0 4 1 2 4 2 0
Flucke et al. [11] 5 2 2 0 0 0 0 0 0 0
Stacchiotti et al. [14] 11 0 0 0 0 0 0 11 0 0
NA indicates non avaliable.
Table 6
Reported cases of Pulmonary Extraskeletal Myxoid Chondrosarcoma.
Case Report Author Publish Year Age Gender Symptoms Primary Site Treatment Follow Up (Months) Outcome
Goetz et al. [19] 1992 66 F Hemoptysis Pleura None NA NA
Ichimura et al. [20] 2004 35 M None Lung Parenchyma Tumor Resection 75 Alive
Zhou  et al. [18] 2013 51 F Severe Anemia Left Upper Lobe Lobectomy with Lymph Node Dissection 32 Alive
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[Gadabanahalli et al. [12] 2015 31 M Dyspnea Pulmona
Present Case 2016 69 M Hemoptysis Right Lo
A indicates non available.
ecade of life. The usual location for EMC  is the lower extrem-
ties, in 62% of the cases, followed by the upper extremities,
bdomen, retroperitoneum, and pelvis. This sarcoma is classiﬁed
s an intermediate-grade neoplasm and is characterized by a long
linical course with high potential for local recurrence and distant
etastasis. Non-surgical treatment for EMC  is usually reserved for
ecurrent or metastatic disease. Pulmonary extraskeletal myxoid
hondrosarcoma is an extremely rare neoplasm with only isolated
ase reports found in the literature.
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